Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04923178 · ClinicalTrials.gov registry record
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
A clinical trial of Bladder Cancer and Urothelial Cancer, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 1,100
- Enrollment target
- 1
- Study location
NCT04923178: Recruiting study of Bladder Cancer and Urothelial Cancer, sponsored by National Cancer Institute (NCI).
NCT04923178 is a study of Bladder Cancer and Urothelial Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 1,100 participants, below the 12,747-participant average among 175 other Bladder Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04923178, a study of Bladder Cancer and Urothelial Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 1,100 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare. Some GU tumors are so rare that they are not included in treatment studies or tissue banks. This makes it hard for researchers to determine standards of care. Researchers want to learn more about common and rare GU tumors. Objective: To learn more about urinary tract cancers. Eligibility: People ages 18 and older with urinary tract or GU cancer such as bladder, kidney, testicular, prostate, penis, or neuroendocrine cancer. Design: Participants will be screened with questions about their medical history. Their medical records will be reviewed. Participants will have a physical exam. They will give blood and urine samples. They will complete a survey about their family cancer history. Clinical photographs will be taken to document skin lesions. Participants may have imaging scans of their chest, abdomen, and pelvis. They may have a contrast agent injected into their arm. Participants will get recommendations about how to best manage and treat their cancer. They can ask as many questions as they would like. Participants will provide existing tumor samples if available. They may have optional tumor biopsies up to twice a year. For needle biopsies, the biopsy area will be numbed and they will get a sedative. A needle will be inserted through their skin to collect a tumor sample. For skin biopsies, their skin will be numbed. A small circle of skin will be removed. Some blood and tumor samples may be used for genetic tests. Participants will have frequent follow-up visits. If they cannot visit NIH, their home doctor will be contacted. They will be followed on this study for life....
Primary Outcome
clinical presentation, patterns of disease progression, therapeutic response, disease recurrence and participant overall survival
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2022-10-24 |
| Est. Completion | 2042-12-01 |
What NCT04923178 shows while recruiting
NCT04923178 is an observational study that tracks outcomes without assigning an intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, below the 12,747-participant average among 175 other Bladder Cancer trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04923178 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04923178 about?
NCT04923178 is a clinical study titled "A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies". Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare. Some GU tumors are so rare that they are not included in treatment studies or tissu...
What is the current status of trial NCT04923178?
This trial is currently recruiting. The enrollment target is 1,100 participants. The study started on 2022-10-24. Estimated completion is 2042-12-01.
What conditions does trial NCT04923178 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer.
Who is sponsoring clinical trial NCT04923178?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04923178 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04923178's enrollment target sits among peer trials
1,100 14th of 175 higher than 162 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI